- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00710112
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants (CLD)
March 14, 2023 updated by: G. Ganesh Konduri, Medical College of Wisconsin
The purpose of this study is to determine if sequence variations in genes involved in the development and function of vulnerable organs increases susceptibility to chronic lung disease (CLD) and other diseases affecting premature infants, such as necrotizing enterocolitis (NEC), sepsis, patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH).
The study will also determine whether measurement of certain biomarkers in serum will identify infants who will develop these complications of prematurity.
Previous studies from this institution and others have identified genetic variants in some genes, such as toll like receptor genes are associated with higher risk of CLD or NEC.
The interaction of these variants with other gene variants that can influence the risk of these diseases remains unclear.
Study Overview
Detailed Description
Chronic lung disease of prematurity (CLD) is diagnosed in 30-40% of very low birth weight (VLBW) infants (<1500gms) and remains a leading cause of mortality and long-term morbidity in this population.
Other diseases such as necrotizing enterocolitis (NEC), sepsis, patent ductus arteriosus (PDA), and intraventricular hemorrhage (IVH) also contribute to mortality and morbidity in this population.
A central tenet in the pathogenesis of NEC, CLD and sepsis is the failure of host genome-regulated immune defenses to surmount the challenges posed by microbial pathogens in the presence of risk-factors that induce intestinal, pulmonary and systemic injury, respectively.
Toll like receptors (TLRs) are pathogen recognition receptors which serve as the recognition and effector arm of the innate immune system.
Since the premature infant is predominantly dependent on the innate immune system for host defense our hypothesis is that hypomorphic genetic variations in TLRs will increase susceptibility to diseases of prematurity such as CLD and sepsis.The increased risk of inflammation, decreased potential for repair and growth of lung may be reflected in the levels of biomarkers, such as, cytokines, micro-RNAs (miRNA) or peptides that are secreted into biological fluids, like blood and tracheal aspirates.
It is likely that the genetic variants that increase the risk of inflammation or decreased repair and growth will be also associated with altered levels of these biomarkers.
Measurement of the biomarkers and genetic variants together can increase the precision of the early predictors of these complications of prematurity.
Measurement of biomarkers in biological fluids can be done with a shorter turnaround time than gene sequencing at the present time.
Biomarkers can also provide longitudinal changes in the severity of disease and response to therapy.
Newer multiplex assays make it feasible to measure the levels of biomarkers in very small quantities of biological fluids.
These complementary strengths make gene sequencing and biomarker detection ideal 1-2 approach for the early identification and disease progression evaluation in premature infants.
Our hypothesis will be tested in VLBW infants in four specific aims: (1) To determine whether the presence of previously described single nucleotide polymorphisms (SNPs) in TLR4 (Asp299Gly, Thr399Ile) TLR2 (Arg753Gln) and TLR5 (Arg392STOP) genes is associated with an increased risk of CLD ; (2) to detect by DNA sequencing if novel genetic variations in TLR4, TLR2, TLR9, MyD88 and other innate immune genes increases the risk of CLD or other disease in premature infants; (3) to identify by gene sequence approach whether variants in other repair and growth genes alter susceptibility to diseases affecting premature infants such as CLD,NEC or sepsis or PDA or IVH; and (4) whether alterations in cytokines, miRNA and other biomarker levels in serum from the same blood samples can provide additional predictive value in recognizing the risk of diseases of prematurity.
VLBW infants who develop CLD (oxygen requirement at 36 weeks postconceptional age), NEC, sepsis, PDA, or IVH will serve as cases while VLBW infants who do not develop the diseases of interest will serve as controls.
A 0.5cc sample of blood will be collected from enrolled infants via indwelling catheter or heel-stick for DNA analysis after consent is obtained.
The TLR4 (Asp299Gly, Thr399Ile) TLR2 (Arg753Gln) and TLR5 (Arg392STOP) SNPs will be evaluated using a multiplex Single Base extension based technique, using commercially available primers.
Novel genetic variations in these genes of interest and other variants proposed to be related to NEC will be detected using conventional Sanger or Next Generation DNA sequencing.
Serum will be separated from the same blood sample obtained for DNA isolation.
A second 0.5cc sample of blood will be collected for biomarker measurement.
Biomarker levels in serum will be analyzed using multiplex EIA for cytokines, sequencing for miRNA profile and ELISA for peptide levels of interest (VEGF, angiopoietin-2 and Nogo-B peptide).
Benefits include the possibility of development of risk-based preventive and therapeutic strategies to prevent CLD, NEC, sepsis, PDA, or IVH in this population.
Study Type
Observational
Enrollment (Anticipated)
1100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: G. Ganesh Konduri, MD
- Phone Number: 414.266.6820
- Email: gkonduri@mcw.edu
Study Contact Backup
- Name: Kathleen M Meskin, BSN
- Phone Number: 414.337.7171
- Email: kmeskin@mcw.edu
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Children's Wisconsin
-
Contact:
- G. Ganesh Konduri, MD
- Phone Number: 414-266-6820
- Email: gkonduri@mcw.edu
-
Principal Investigator:
- G. Ganesh Konduri, MD
-
Contact:
- Kathleen Meskin, RN, BSN
- Phone Number: 414-337-7171
- Email: kmeskin@mcw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Infants born weighing less than 1500 grams
Description
Inclusion Criteria:
- Infants born weighing less than 1500 grams
Exclusion Criteria:
- Infants born with congenital heart disease (other than patent ductus arteriosus)
- major congenital anomalies of the GI tract, respiratory tract, or kidneys
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
VLBW
infants less than 1500 grams at birth
|
comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if small variations in certain genes predispose infants to the development of chronic lung disease and other diseases of prematurity
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 to 8 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 6 to 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: G. Ganesh Konduri, MD, Medical College of Wisconsin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Anticipated)
June 1, 2025
Study Completion (Anticipated)
June 1, 2026
Study Registration Dates
First Submitted
June 19, 2008
First Submitted That Met QC Criteria
July 3, 2008
First Posted (Estimate)
July 4, 2008
Study Record Updates
Last Update Posted (Actual)
March 16, 2023
Last Update Submitted That Met QC Criteria
March 14, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHW 06/92, GC151
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lung Disease
-
Sygehus LillebaeltDanmarks Lungeforening; Chiesi Foundation; Overlæge Jørgen Werner Schous og hustru...Active, not recruitingChronic Obstructive Pulmonary DiseaseDenmark
-
Breathe Technologies, Inc.CompletedPulmonary Disease, Chronic Obstructive | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease | Airflow Obstruction, ChronicUnited States
-
Centre Hospitalier Intercommunal CreteilRecruitingChronic Obstructive Pulmonary Disease | Chronic Obstructive Lung DiseaseFrance
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Obstructive Lung Disease (COLD)France
-
Breathe Technologies, Inc.CompletedPulmonary Disease, Chronic Obstructive | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease | Airflow Obstruction, ChronicUnited States
-
Aveiro UniversityPrograma Operacional Inclusão Social e Emprego (POISE); Programa Operacional... and other collaboratorsCompletedLung Diseases | Chronic Obstructive Pulmonary Disease | Pulmonary Disease | Interstitial Lung Disease | Chronic Respiratory DiseasePortugal
-
Icahn School of Medicine at Mount SinaiUniversity of Pittsburgh; Brigham and Women's Hospital; University of New Mexico and other collaboratorsActive, not recruitingLung Cancer | Interstitial Lung Disease | Chronic Airway DiseaseUnited States
-
Beni-Suef UniversityCompleted
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Lung Disease (n=10) | Interstitial Lung Disease (n=10)Germany
-
King's College Hospital NHS TrustNot yet recruitingBronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Lung Cancer | Interstitial Lung Disease | Chronic Lung Disease | Dyspnea | Fibrotic Lung DiseaseUnited Kingdom
Clinical Trials on gene variations
-
University Hospital, LilleTerminatedSystemic Inflammatory Response Syndrome | Mechanical Ventilation | Circulatory FailureFrance
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University of PrimorskaUnknown
-
Maastricht University Medical CenterUnknown
-
Elif AYGUN POLATGazi UniversityCompleted
-
Jens Rikardt AndersenCompleted
-
University of PaviaCompleted
-
University Hospital, Clermont-FerrandUnknown
-
Palo Alto Veterans Institute for ResearchCompleted